HLS announces that Vascepa is now reimbursed by British Columbia's Provincial Drug Plan

6 February 2024 - Public reimbursement for Vascepa is now available in Ontario, Quebec, British Columbia, Saskatchewan, New Brunswick, Northwest Territories, ...

Read more →

AbbVie announces provincial reimbursement for Vraylar (cariprazine) for the treatment of schizophrenia in Québec

17 April 2023 - AbbVie today announced that Vraylat is now listed as an exception medication status on the list of ...

Read more →

Mitsubishi Tanabe Pharma Canada receives engagement letter from Pan-Canadian Pharmaceutical Alliance for Radicava oral suspension

31 March 2023 - Mitsubishi Tanabe Pharma Canada is pleased to announce the company has entered into negotiations with the ...

Read more →

Valeo Pharma obtains public reimbursement for Onstryv in Quebec

7 February 2023 - Quebec public reimbursement coverage to facilitate and expand medication access for Parkinson’s patients in Quebec. ...

Read more →

Medexus secures public reimbursement for Cuvposa in Quebec

1 February 2023 - Medexus Pharmaceuticals wishes to inform investors that the company has reached an agreement with the provincial government ...

Read more →

HLS announces that Vascepa is now reimbursed by Ontario's Provincial Drug Plan

25 July 2022 - Reimbursement for Vascepa in Canada is now at more than 65% for publicly covered lives and private ...

Read more →

Canada making progress in prescription drug coverage

13 July 2022 - Canada has seen a significant improvement in the number of Canadians eligible for some form of prescription ...

Read more →

Valeo Pharma secures additional public reimbursement for Redesca, Enerzair Breezhaler and Atectura Breezhaler

22 March 2022 - Canadian provincial public reimbursement now complete for Redesca with the addition of British Columbia. ...

Read more →

CADTH calls for patient input

26 August 2015 - CADTH has received notice of a pending submission from ApoPharma for deferiprone (Ferriprox) for patients with transfusional ...

Read more →